Recombinant interferon‐α in inoperable hepatocellular carcinoma: A randomized controlled trial
Ching‐Lung Lai, Johnson Y. N. Lau, Pui‐Chee Wu, Henry Ngan, Hau‐Tim Chung, Stuart J. Mitchell, Timothy J. Corbett, Anthony W. C. Chow, Hsiang‐Ju Lin – 1 March 1993 – To evaluate the clinical efficacy of interferon‐α in hepatocellular carcinoma, 71 adult Chinese patients with histologically proven inoperable hepatocellular carcinoma were randomized to receive recombinant interferon‐α2a (50 × 106 IU/m2) intramuscularly three times a week (n = 35) or no antitumor therapy (n = 36).